Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 321-329

  Knappe, Daniel ^a,b   Cassone, Marco ^c   Nollmann, Friederike Inga ^a,b   Otvos Jr , Laszlo ^c   Hoffmann, Ralf ^a,b  

^a Faculty of Chemistry and Mineralogy   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Temple University   (United States)

Author keywords

Antimicrobial peptide (AMP); Escherichia coli; Hydroxyproline; Serum stability; Solid phase peptide synthesis

Indexed keywords

DROSOCIN; HYDROXYPROLINE;

AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DETERMINATION; DRUG EFFECT; DRUG HALF LIFE; DRUG STABILITY; EMBRYO; ERYTHROCYTE; ESCHERICHIA COLI; HEMOLYSIS; HUMAN; HUMAN CELL; KLEBSIELLA PNEUMONIAE; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SUBSTITUTION REACTION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; DRUG STABILITY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GLYCOPEPTIDES; GLYCOSYLATION; HALF-LIFE; HUMANS; HYDROXYPROLINE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PEPTIDES;

EID: 84896358193     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660105     Document Type: Article

References (41)

1. Livermore, D. M.; Warner, M.; Mushtaq, S.; Doumith, M.; Zhang, J.C.; Woodford, N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents, 2011, 37(5), 415-419.
2. Epidemiological Report on Communicable Diseases in Europe 2010; European Centre for Disease Prevention and Control: Stockholm, 10.
3. World Health Day: Media Fact Sheet, Antimicrobial resistance: no action today, no cure tomorrow. 2011. Centers for Disease Control and Prevention. Ref Type: Data File
4. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin. Infect. Dis., 2009, 48(1), 1-12.
5. Bush, K.; Pucci, M.J. New antimicrobial agents on the horizon. Biochem. Pharmacol., 2011, 82(11), 1528-1539.
6. Yount, N.Y.; Bayer, A.S.; Xiong, Y.Q.; Yeaman, M.R. Advances in antimicrobial peptide immunobiology. Biopolymers, 2006, 84(5), 435-458.
7. Boman, H.G. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med., 2003, 254(3), 197-215.
8. Jenssen, H.; Hamill, P.; Hancock, R.E.W. Peptide antimicrobial agents. Clin. Microbiol. Rev., 2006, 19(3), 491-511.
9. Otvos, L. The short proline-rich antibacterial peptide family. Cell. Mol. Life Sci., 2002, 59(7), 1138-1150.
10. Benincasa, M.; Pelillo, C.; Zorzet, S.; Garrovo, C.; Biffi, S.; Gennaro, R.; Scocchi, M. The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol., 2010, 10(178), 178.
11. Ostorhazi, E.; Rozgonyi, F.; Szabo, D.; Binas, A.; Cassone, M.; Wade, J.D.; Nolte, O.; Bethel, C.R.; Bonomo, R.A.; Otvos, L. Intramuscularly adminsistered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections. Biopolymers, 2010, [Epub ahead of print].
12. Knappe, D.; Fritsche, S.; Alber, G.; Kohler, G.; Hoffmann, R.; Muller, U. Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model. J. Antimicrob. Chemother., 2012, 67(10), 2445-2451.
13. Czihal, P.; Knappe, D.; Fritsche, S.; Zahn, M.; Berthold, N.; Piantavigna, S.; Muller, U.; Van Dorpe, S.; Herth, N.; Binas, A.; Kohler, G.; De Spiegeleer, B.; Martin, L.L.; Nolte, O.; Strater, N.; Alber, G.; Hoffmann, R. Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens. ACS Chem. Biol., 2012, 7(7), 1281-1291.
14. Bulet, P.; Urge, L.; Ohresser, S.; Hetru, C.; Otvos, L. Enlarged scale chemical synthesis and range of activity of drosocin, an Oglycosylated antibacterial peptide of Drosophila. Eur. J. Biochem., 1996, 238(1), 64-69.
15. McManus, A.M.; Otvos, L.; Hoffmann, R.; Craik, D.J. Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: Effects of glycosylation on solution conformation. Biochemistry, 1999, 38(2), 705-714.
16. Hoffmann, R.; Bulet, P.; Urge, L.; Otvos, L. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim. Biophys. Acta, 1999, 1426(3), 459-467.
17. Bulet, P.; Dimarcq, J.L.; Hetru, C.; Lagueux, M.; Charlet, M.; Hegy, G.; Vandorsselaer, A.; Hoffmann, J.A. A Novel Inducible Antibacterial Peptide of Drosophila Carries An O-Glycosylated Substitution. J. Biol. Chem., 1993, 268(20), 14893-14897.
18. Cociancich, S.; Dupont, A.; Hegy, G.; Lanot, R.; Holder, F.; Hetru, C.; Hoffmann, J.A.; Bulet, P. Novel Inducible Antibacterial Peptides from A Hemipteran Insect, the Sap-Sucking Bug Pyrrhocoris-Apterus. Biochem. J., 1994, 300, 567-575.
19. Mackintosh, J.A.; Veal, D.A.; Beattie, A.J.; Gooley, A.A. Isolation from an ant Myrmecia gulosa of two inducible O-glycosylated proline-rich antibacterial peptides. J. Biol. Chem., 1998, 273(11), 6139-6143.
20. de Visser, P.C.; van Hooft, P.A.V.; de Vries, A.M.; de Jong, A.; van der Marel, G.A.; Overkleeft, H.S.; Noort, D. Biological evaluation of Tyr6 and Ser7 modified drosocin analogues. Bioorg. Med. Chem. Lett., 2005, 15(11), 2902-2905.
21. Bikker, F.J.; Kaman-van Zanten, W.E.; de Vries-van de Ruit; van Hooft, P.A.V.; Mars-Groenendijk, R.H.; de Visser, P.C.; Noort, D. Evaluation of the antibacterial spectrum of drosocin analogues. Chem. Biol. Drug Des., 2006, 68(3), 148-153.
22. Ahn, M.; Sohn, H.; Nan, Y.H.; Murugan, R.N.; Cheong, C.; Ryu, E.K.; Kim, E.H.; Kang, S.W.; Kim, E.J.; Shin, S.Y.; Bang, J.K. Functional and Structural Characterization of Drosocin and its Derivatives Linked O-GalNAc at Thr(11) Residue. Bull. Korean Chem. Soc., 2011, 32(9), 3327-3332.
23. Ahn, M.; Murugan, R.N.; Nan, Y.H.; Cheong, C.; Sohn, H.; Kim, E.H.; Hwang, E.; Ryu, E.K.; Kang, S.W.; Shin, S.Y.; Bang, J.K. Substitution of the GalNAc-alpha-O-Thr(11) residue in drosocin with O-linked glyco-peptoid residue: Effect on antibacterial activity and conformational change. Bioorg. Med. Chem. Lett., 2011, 21(20), 6148-6153.
24. Talat, S.; Thiruvikraman, M.; Kumari, S.; Kaur, K.J. Glycosylated analogs of formaecin I and drosocin exhibit differential pattern of antibacterial activity. Glycoconj. J., 2011, 28(8-9), 537-555.
25. Otvos, L.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry, 2000, 39(46), 14150-14159.
26. Zahn, M.; Berthold, N.; Kieslich, B.; Knappe, D.; Hoffmann, R.; Strater, N. Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK. J. Mol. Biol., 2013, [Epub ahead of print].
27. Knappe, D.; Piantavigna, S.; Hansen, A.; Mechler, A.; Binas, A.; Nolte, O.; Martin, L.L.; Hoffmann, R. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): A Novel Antibacterial Peptide Optimized Against Gram-Negative Human Pathogens. J. Med. Chem., 2010, 53(14), 5240-5247.
28. Raillard, S.P.; Mann, A.D.; Baer, T.A. An Efficient Procedure for the Preparation of Fmoc-Amino-Acids. Org. Prep. Proced. Int., 1998, 30(2), 183-186.
29. Hoffmann, R.; Vasko, M.; Otvos, L. Serum stability of phosphopeptides. Anal. Chim. Acta, 1997, 352(1-3), 319-325.
30. Knappe, D.; Zahn, M.; Sauer, U.; Schiffer, G.; Strater, N.; Hoffmann, R. Rational Design of Oncocin Derivatives with Superior Protease Stabilities and Antibacterial Activities Based on the High-Resolution Structure of the Oncocin-DnaK Complex. ChemBioChem, 2011, 12(6), 874-876.
31. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry, 2001, 40(10), 3016-3026.
32. Czihal, P.; Hoffmann, R. Mapping of Apidaecin Regions Relevant for Antimicrobial Activity and Bacterial Internalization. Int. J. Pept. Res. Ther., 2009, 15(2), 157-164.
33. Otvos, L.; Wade, J.D.; Lin, F.; Condie, B.A.; Hanrieder, J.; Hoffmann, R. Designer antibacterial peptides kill fluoroquinoloneresistant clinical isolates. J. Med. Chem., 2005, 48(16), 5349-5359.
34. Berthold, N.; Czihal, P.; Fritsche, S.; Sauer, U.; Schiffer, G.; Knappe, D.; Alber, G.; Hoffmann, R. Novel Apidaecin 1b Analogs with Superior Serum Stabilities for Treatment of Infections by Gram-Negative Pathogens. Antimicrob. Agents Chemother., 2013, 57(1), 402-409.
35. Szabo, D.; Ostorhazi, E.; Binas, A.; Rozgonyi, F.; Kocsis, B.; Cassone, M.; Wade, J.D.; Nolte, O.; Otvos, L. The designer prolinerich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int. J. Antimicrob. Agents, 2010, 35(4), 357-361.
36. Gennaro, R.; Zanetti, M.; Benincasa, M.; Podda, E.; Miani, M. Prorich antimicrobial peptides from animals: Structure, biological functions and mechanism of action. Curr. Pharmaceut. Des., 2002, 8(9), 763-778.
37. Mattiuzzo, M.; Bandiera, A.; Gennaro, R.; Benincasa, M.; Pacor, S.; Antcheva, N.; Scocchi, M. Role of the Escherichia coli SbmA in the antimicrobial activity of proline-rich peptides. Mol. Microbiol., 2007, 66(1), 151-163.
38. Stewart, J.M.; Ryan, J.W.; Brady, A.H. Hydroxyproline analogs of bradykinin. J. Med. Chem., 1974, 17(5), 537-539.
39. Thomas, K.M.; Naduthambi, D.; Zondlo, N.J. Electronic control of amide cis-trans isomerism via the aromatic-prolyl interaction. J. Am. Chem. Soc., 2006, 128(7), 2216-2217.
40. Bhattacharyya, R.; Chakrabarti, P. Stereospecific Interactions of Proline Residues in Protein Structures and Complexes. J. Mol. Biol., 2003, 331(4), 925-940.
41. Zheng, T.Y.; Lin, Y.J.; Horng, J.C. Thermodynamic Consequences of Incorporating 4-Substituted Proline Derivatives into a Small Helical Protein. Biochemistry, 2010, 49(19), 4255-4263.